# Poseida Therapeutics

Source: https://onco.cc/companies/poseida-therapeutics/  
OnCo record `poseida-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Poseida developed off-the-shelf CAR T-cell therapies made from healthy donor cells rather than from each patient, for multiple myeloma and B-cell cancers. Roche bought the company in early 2025 for up to about $1.5 billion.

## Summary

Poseida Therapeutics was a clinical-stage company pioneering donor-derived (allogeneic) CAR T-cell therapies, with non-viral piggyBac gene engineering and manufacturing capabilities. Lead programme P-BCMA-ALLO1 is an allogeneic BCMA-directed CAR T for relapsed or refractory multiple myeloma with RMAT and Orphan Drug designations. P-CD19CD20-ALLO1 is a phase 1 allogeneic dual CAR T in B-cell malignancies, also being investigated in multiple sclerosis and lupus, and P-MUC1C-ALLO1 is a phase 1 allogeneic CAR T in solid tumours. Several programmes were already partnered with Roche under a 2022 collaboration. Roche agreed in November 2024 to acquire Poseida for $9.00 per share in cash plus a contingent value right worth up to $4.00 per share, a total of up to about $1.5 billion, and the merger closed on 8 January 2025. Legacy programmes continue within Genentech and the former Nasdaq ticker PSTX was retired.

## Fields

- Kind: Company
- Last checked: 2026-09-10
- HQ: San Diego, CA
- Type: cell-therapy
- Website: https://www.gene.com/poseida

## Notes

- Former Nasdaq ticker PSTX. The CVR portion of the deal value is contingent on milestones.

## Sources

- Official website: https://www.gene.com/poseida
- Roche to acquire Poseida (November 2024): https://www.roche.com/media/releases/med-cor-2024-11-26b
- Completion of merger (8-K, January 2025): https://www.sec.gov/Archives/edgar/data/1661460/000119312525003248/d874651d8k.htm

## Connected records

- cancers: [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/), [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- fronts: [Cell Therapy](https://onco.cc/fronts/cell-therapy/)
- technologies: [Allogeneic (off-the-shelf) cell therapy](https://onco.cc/technologies/allogeneic-cell-therapy/), [CAR-T cell therapy](https://onco.cc/technologies/car-t/)
- targets: [BCMA](https://onco.cc/targets/bcma/), [CD19](https://onco.cc/targets/cd19/), [CD20](https://onco.cc/targets/cd20/)
- companies: [Roche / Genentech](https://onco.cc/companies/roche-genentech/)

---
JSON: https://onco.cc/api/v1/entities/poseida-therapeutics.json